Developer docs
API playgroundTry for free, no card

Search company profiles

EpiBone

Full company profile

uuid0000eht

Namestring
EpiBone
Legal namestring
EpiBone, Inc.
Websiteurl
epibone.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts from a patient's own stem cells using proprietary bioreactor technology. Founded in 2013 and headquartered in Brooklyn, NY, the company targets skeletal conditions — which it identifies as the leading cause of disability worldwide — by growing living, anatomically precise tissue grafts in approximately 3 weeks (bone) to 4 weeks (cartilage) that are designed to integrate, remodel, and adapt with the patient, eliminating the need for synthetic implants or secondary surgical harvest sites.

The company's technology platform combines CT scan-guided 3D shape customization, stem cell sourcing (from patient abdominal fat for autologous products, from cell banks for allogeneic products), and a proprietary bioreactor that emulates natural tissue development conditions through controlled oxygen, nutrient, and mechanical loading. The pipeline includes three products: EB-CM, an autologous craniofacial bone graft (Phase I/IIa completed in 2023); EB-OC, an allogeneic tissue-engineered osteochondral plug for high-grade cartilage lesions (FDA IND approved for a Phase I/IIb trial in 36 patients); and EB-iAC, an injectable allogeneic cartilage filler for low-grade lesions with up to 2 years of storage stability.

EpiBone is pre-commercial and pre-revenue. Future revenue is expected to come from direct hospital and specialty clinic distribution of patient-specific living tissue grafts to oral/maxillofacial surgeons, orthopedic sports medicine specialists, and craniofacial reconstruction teams — a procedure-linked, high-value model analogous to advanced biologics and cell therapy commercialization. The company has raised approximately $35M+ across multiple funding rounds from 2014 through 2025, with backing from NetScientific PLC, Kendall Capital Partners, Covenant Venture Capital, Tachyon Ventures, Plum Alley, Breakout Labs, and others. Strategic and academic ties to Columbia University (co-founder origin, board representation) and MIT (Dr. Robert Langer on the board) reinforce its research foundation.

Short descriptiontext

EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts grown from a patient's own stem cells using proprietary bioreactor technology, targeting craniofacial reconstruction and orthopedic joint repair patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBrooklyn, United States
HQ citystring
Brooklyn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, bone tissue engineering, cartilage regeneration, stem cell therapy, personalized implants
Industry4 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLABAEAB
Dental Implant Surgery & Bone Grafting
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Tissue Engineering
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Regenerative Tissue Products (Pipeline)
TypeOne Time License
Description

EpiBone is a pre-commercial, clinical-stage company. Its revenue model will derive from the sale of personalized, tissue-engineered bone and cartilage grafts. Products EB-CM (autologous craniofacial bone), EB-OC (osteochondral plug), and EB-iAC (injectable cartilage) are in various stages of clinical development. Revenue will come from direct supply of patient-specific living tissue grafts to hospital systems, orthopedic surgeons, and oral/maxillofacial surgeons — a high-value, procedure-linked model akin to advanced biologics and cell therapy commercialization.

epibone.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EpiBone is a clinical-stage regenerative medicine company that grows personalized bone and cartilage grafts from a patient's own stem cells (or donor-derived cells for allogeneic products) using proprietary bioreactor technology and 3D bioprinting. Its pipeline includes EB-CM (autologous craniofacial bone graft), EB-OC (allogeneic osteochondral plug), and EB-iAC (injectable allogeneic cartilage), each cultivated in 3-4 weeks for skeletal reconstruction procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Craniofacial bone reconstruction using tissue-engineered autologous grafts — Phase I/IIa clinical trial completed 2023
+4 more records
Product overview1 text field

EpiBone is a regenerative medicine company offering a platform of tissue-engineered bone and cartilage products grown from stem cells using proprietary bioreactor technology. The product portfolio consists of three core offerings: EB-CM for craniofacial bone reconstruction, EB-OC for osteochondral joint repair, and EB-iAC for injectable cartilage treatment. All products leverage stem cell extraction, 3D customization via CT scanning, and bioreactor-based tissue growth to create personalized, living tissue grafts that eliminate the need for artificial implants.

Product and service3 records
1EB-CM (EpiBone-Craniomaxillofacial)
CategoryCraniofacial Bone Graft
Description

Tissue-engineered autologous bone graft product for craniofacial defects resulting from trauma, congenital defects, or degenerative bone disease. Customized for patients via CT scan with stem cells extracted from patients' abdominal fat and cultivated in a proprietary bioreactor. Indicated for facial bone reconstruction procedures performed by oral and maxillofacial surgeons.

2EB-OC (EpiBone-Osteochondral)
CategoryOsteochondral Plug
Description

Allogeneic, tissue-engineered osteochondral plug for treating high-grade cartilage lesions in healthy joints. Composed of condensed mesenchymal cells from donor bone marrow encapsulated in hydrogel and cultivated on a bone scaffold in a bioreactor with cyclical mechanical loading and perfusion. Designed for orthopedic sports medicine and joint surgery specialists.

3EB-iAC (EpiBone-injectable Articular Cartilage)
CategoryInjectable Cartilage Filler
Description

Allogeneic, injectable cartilage product for treating low-grade cartilage lesions that do not involve underlying bone. Stem cells from a cell bank are processed into condensed mesenchymal cells primed for cartilage formation, combined with a hydrogel carrier, and delivered via injection. Components can be stored for up to 2 years.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EpiBone originated from Columbia University research. Co-Founders Dr. Nina Tandon and Dr. Sarindr Bhumiratana completed their PhDs and postdocs at Columbia. Board member Dr. Gordana Vunjak-Novakovic directs the Laboratory for Stem Cells & Tissue Engineering at Columbia. The company leverages Columbia's research infrastructure and academic talent pipeline.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bioventus offers orthobiologic solutions including bone graft substitutes and cartilage repair products. Comparable as a commercial-stage orthobiologics incumbent serving overlapping orthopedic surgeon customers, though with synthetic/allograft rather than living-cell technology.

TypeEmerging player
Description

MiMedx develops placental tissue allografts for wound care and surgical applications in regenerative medicine. Comparable as an emerging peer in the regenerative tissue space serving surgical specialties with biologically-derived grafts.

TypeDirect peer
Description

Vericel markets MACI, an FDA-approved autologous cultured chondrocyte implant for cartilage repair of the knee — the closest direct competitor to EpiBone's EB-OC osteochondral plug and EB-iAC injectable cartilage products, with an established US commercial infrastructure in sports medicine.

TypeDirect peer
Description

Mesoblast develops allogeneic cellular medicines for inflammatory and orthopedic conditions, including cartilage and bone indications. Comparable as a clinical/late-stage cell therapy company targeting musculoskeletal regeneration with stem-cell-based platforms.

TypeBroad incumbent
Description

Stryker is a global orthopedics and medical device leader with significant investments in regenerative and biologic solutions for bone and joint repair. Comparable as a large incumbent whose sports medicine and orthobiologics franchises compete with EpiBone's target surgeon customers.

TypeBroad incumbent
Description

Organogenesis is a leading regenerative medicine company commercializing living-cell-based wound care and surgical biologics (Apligraf, Dermagraft). Comparable as a broader commercial-stage regenerative medicine incumbent using living cell-based products, though focused on skin/soft tissue rather than skeletal.

TypeDirect peer
Description

Histogenics developed NeoCart, an autologous tissue-engineered cartilage implant — directly analogous in product concept (patient-specific, cell-based cartilage graft) to EpiBone's EB-OC. Acquired/merged with Ocugen; serves as a reference case for the cartilage tissue engineering space.

TypeBroad incumbent
Description

Integra LifeSciences develops regenerative tissue technologies including dural repair and dermal regeneration products using collagen and tissue-engineering approaches. Comparable as a diversified regenerative medicine incumbent with overlapping surgical customer channels.

TypeBroad incumbent
Description

Smith+Nephew acquired CartiHeal (Agili-C), an FDA-approved cartilage repair implant, positioning them in the regenerative cartilage space. Comparable as a major orthopedic incumbent actively building a cartilage regeneration portfolio through M&A.

TypeDirect peer
Description

CartiHeal developed the Agili-C cartilage repair scaffold, now FDA-approved and acquired by Smith+Nephew. Comparable as a direct cartilage regeneration product peer targeting similar orthopedic indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EpiBone

Tissue Engineeringepibone.com

EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts grown from a patient's own stem cells using proprietary bioreactor technology, targeting craniofacial reconstruction and orthopedic joint repair patients.

What EpiBone does

EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts from a patient's own stem cells using proprietary bioreactor technology. Founded in 2013 and headquartered in Brooklyn, NY, the company targets skeletal conditions — which it identifies as the leading cause of disability worldwide — by growing living, anatomically precise tissue grafts in approximately 3 weeks (bone) to 4 weeks (cartilage) that are designed to integrate, remodel, and adapt with the patient, eliminating the need for synthetic implants or secondary surgical harvest sites.

The company's technology platform combines CT scan-guided 3D shape customization, stem cell sourcing (from patient abdominal fat for autologous products, from cell banks for allogeneic products), and a proprietary bioreactor that emulates natural tissue development conditions through controlled oxygen, nutrient, and mechanical loading. The pipeline includes three products: EB-CM, an autologous craniofacial bone graft (Phase I/IIa completed in 2023); EB-OC, an allogeneic tissue-engineered osteochondral plug for high-grade cartilage lesions (FDA IND approved for a Phase I/IIb trial in 36 patients); and EB-iAC, an injectable allogeneic cartilage filler for low-grade lesions with up to 2 years of storage stability.

EpiBone is pre-commercial and pre-revenue. Future revenue is expected to come from direct hospital and specialty clinic distribution of patient-specific living tissue grafts to oral/maxillofacial surgeons, orthopedic sports medicine specialists, and craniofacial reconstruction teams — a procedure-linked, high-value model analogous to advanced biologics and cell therapy commercialization. The company has raised approximately $35M+ across multiple funding rounds from 2014 through 2025, with backing from NetScientific PLC, Kendall Capital Partners, Covenant Venture Capital, Tachyon Ventures, Plum Alley, Breakout Labs, and others. Strategic and academic ties to Columbia University (co-founder origin, board representation) and MIT (Dr. Robert Langer on the board) reinforce its research foundation.

EpiBone firmographics

Firmographics
Name
EpiBone
Legal name
EpiBone, Inc.
Website
https://epibone.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts grown from a patient's own stem cells using proprietary bioreactor technology, targeting craniofacial reconstruction and orthopedic joint repair patients.
Ownership category
akta.pro rank

EpiBone industry classification

Industry
Product category
Tissue Engineering
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLABAEAB
Dental Implant Surgery & Bone Grafting

Keywords

  • Regenerative medicine
  • Bone tissue engineering
  • Cartilage regeneration
  • Stem cell therapy
  • Personalized implants

Where EpiBone is headquartered

Location

Headquarters

HQ city
Brooklyn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EpiBone business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Regenerative Tissue Products (Pipeline): EpiBone is a pre-commercial, clinical-stage company. Its revenue model will derive from the sale of personalized, tissue-engineered bone and cartilage grafts. Products EB-CM (autologous craniofacial bone), EB-OC (osteochondral plug), and EB-iAC (injectable cartilage) are in various stages of clinical development. Revenue will come from direct supply of patient-specific living tissue grafts to hospital systems, orthopedic surgeons, and oral/maxillofacial surgeons — a high-value, procedure-linked model akin to advanced biologics and cell therapy commercialization.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels3 records

EpiBone product offering

Product offering

Core offering

EpiBone is a clinical-stage regenerative medicine company that grows personalized bone and cartilage grafts from a patient's own stem cells (or donor-derived cells for allogeneic products) using proprietary bioreactor technology and 3D bioprinting. Its pipeline includes EB-CM (autologous craniofacial bone graft), EB-OC (allogeneic osteochondral plug), and EB-iAC (injectable allogeneic cartilage), each cultivated in 3-4 weeks for skeletal reconstruction procedures.

Product overview

EpiBone is a regenerative medicine company offering a platform of tissue-engineered bone and cartilage products grown from stem cells using proprietary bioreactor technology. The product portfolio consists of three core offerings: EB-CM for craniofacial bone reconstruction, EB-OC for osteochondral joint repair, and EB-iAC for injectable cartilage treatment. All products leverage stem cell extraction, 3D customization via CT scanning, and bioreactor-based tissue growth to create personalized, living tissue grafts that eliminate the need for artificial implants.

Differentiator

Problem solved

Functional benefit

Products and services

  • EB-CM (EpiBone-Craniomaxillofacial) Tissue-engineered autologous bone graft product for craniofacial defects resulting from trauma, congenital defects, or degenerative bone disease. Customized for patients via CT scan with stem cells extracted from patients' abdominal fat and cultivated in a proprietary bioreactor. Indicated for facial bone reconstruction procedures performed by oral and maxillofacial surgeons.
  • EB-OC (EpiBone-Osteochondral) Allogeneic, tissue-engineered osteochondral plug for treating high-grade cartilage lesions in healthy joints. Composed of condensed mesenchymal cells from donor bone marrow encapsulated in hydrogel and cultivated on a bone scaffold in a bioreactor with cyclical mechanical loading and perfusion. Designed for orthopedic sports medicine and joint surgery specialists.
  • EB-iAC (EpiBone-injectable Articular Cartilage) Allogeneic, injectable cartilage product for treating low-grade cartilage lesions that do not involve underlying bone. Stem cells from a cell bank are processed into condensed mesenchymal cells primed for cartilage formation, combined with a hydrogel carrier, and delivered via injection. Components can be stored for up to 2 years.

Quantifiable outcome

  • Craniofacial bone reconstruction using tissue-engineered autologous grafts — Phase I/IIa clinical trial completed 2023
  • +4 more outcomes

Companies that use EpiBone

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

EpiBone technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

EpiBone partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Columbia UniversitycoreStrategic or Co-development PartnerEpiBone originated from Columbia University research. Co-Founders Dr. Nina Tandon and Dr. Sarindr Bhumiratana completed their PhDs and postdocs at Columbia. Board member Dr. Gordana Vunjak-Novakovic directs the Laboratory for Stem Cells & Tissue Engineering at Columbia. The company leverages Columbia's research infrastructure and academic talent pipeline.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

EpiBone competitors and assessment

Company assessment

Broad incumbents

  • Bioventus: Bioventus offers orthobiologic solutions including bone graft substitutes and cartilage repair products. Comparable as a commercial-stage orthobiologics incumbent serving overlapping orthopedic surgeon customers, though with synthetic/allograft rather than living-cell technology.
  • Stryker: Stryker is a global orthopedics and medical device leader with significant investments in regenerative and biologic solutions for bone and joint repair. Comparable as a large incumbent whose sports medicine and orthobiologics franchises compete with EpiBone's target surgeon customers.
  • Organogenesis: Organogenesis is a leading regenerative medicine company commercializing living-cell-based wound care and surgical biologics (Apligraf, Dermagraft). Comparable as a broader commercial-stage regenerative medicine incumbent using living cell-based products, though focused on skin/soft tissue rather than skeletal.
  • Integra LifeSciences: Integra LifeSciences develops regenerative tissue technologies including dural repair and dermal regeneration products using collagen and tissue-engineering approaches. Comparable as a diversified regenerative medicine incumbent with overlapping surgical customer channels.
  • Smith+Nephew (CartiHeal): Smith+Nephew acquired CartiHeal (Agili-C), an FDA-approved cartilage repair implant, positioning them in the regenerative cartilage space. Comparable as a major orthopedic incumbent actively building a cartilage regeneration portfolio through M&A.

Emerging players

  • MiMedx: MiMedx develops placental tissue allografts for wound care and surgical applications in regenerative medicine. Comparable as an emerging peer in the regenerative tissue space serving surgical specialties with biologically-derived grafts.

Direct peers

  • Vericel: Vericel markets MACI, an FDA-approved autologous cultured chondrocyte implant for cartilage repair of the knee — the closest direct competitor to EpiBone's EB-OC osteochondral plug and EB-iAC injectable cartilage products, with an established US commercial infrastructure in sports medicine.
  • Mesoblast: Mesoblast develops allogeneic cellular medicines for inflammatory and orthopedic conditions, including cartilage and bone indications. Comparable as a clinical/late-stage cell therapy company targeting musculoskeletal regeneration with stem-cell-based platforms.
  • Histogenics (now Ocugen via merger; NeoCart legacy): Histogenics developed NeoCart, an autologous tissue-engineered cartilage implant — directly analogous in product concept (patient-specific, cell-based cartilage graft) to EpiBone's EB-OC. Acquired/merged with Ocugen; serves as a reference case for the cartilage tissue engineering space.
  • CartiHeal (now part of Smith+Nephew): CartiHeal developed the Agili-C cartilage repair scaffold, now FDA-approved and acquired by Smith+Nephew. Comparable as a direct cartilage regeneration product peer targeting similar orthopedic indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

EpiBone social profiles

Digital presence

EpiBone financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EpiBone leadership team

Management profile

Number of profiles

Profiles4 records

EpiBone funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EpiBone M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiBone

What does EpiBone do?

EpiBone is a clinical-stage regenerative medicine company that grows personalized bone and cartilage grafts from a patient's own stem cells (or donor-derived cells for allogeneic products) using proprietary bioreactor technology and 3D bioprinting. Its pipeline includes EB-CM (autologous craniofacial bone graft), EB-OC (allogeneic osteochondral plug), and EB-iAC (injectable allogeneic cartilage), each cultivated in 3-4 weeks for skeletal reconstruction procedures.

Is EpiBone a public or private company?

EpiBone is a private company. It is classified as venture growth investor backed and is currently operating.

When was EpiBone founded?

EpiBone was founded in 2013. It employs 11 to 50 people.

Where is EpiBone based?

EpiBone is headquartered in Brooklyn, United States, in the North America region.

How does EpiBone make money?

One revenue line is on record: regenerative Tissue Products (Pipeline).

Who are EpiBone's main competitors?

Broad incumbents on record are Bioventus, Stryker, Organogenesis, Integra LifeSciences and Smith+Nephew (CartiHeal). MiMedx is listed as an emerging player. Direct peers are Vericel, Mesoblast, Histogenics (now Ocugen via merger; NeoCart legacy) and CartiHeal (now part of Smith+Nephew).

Does EpiBone have an API?

No public API is recorded for EpiBone.

What industry is EpiBone in?

EpiBone's product category is Tissue Engineering. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 334510 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DEpiBone, Inc., a Delaware-incorporated biotechnology company headquartered in New York, filed a Form D notice with the SEC on October 24, 2025, for an exempt offering of equity securities under Rule 506(b). The offering raised a total of $4,300,506 USD, with $4,287,429 already sold to 131 investors as of the first sale date of September 2, 2025. The filing identifies five executive officers and directors including CEO Nina Tandon, and indicates the company operates in the Health Care/Biotechnology sector with the offering expected to last less than one year.MagnoliatribuneTandon to speak on trailblazing regenerative medicine at Southern Miss University ForumDr. Nina Tandon, CEO of EpiBone, will present on regenerative medicine at Southern Miss University Forum on October 21. EpiBone is the first company FDA-cleared to implant engineered living bone, with a second clearance for partial knee replacement in 2023. The presentation will highlight how the technology reshapes healthcare and the economy.NebraskaEpiBone CEO and co-founder to speak at NebraskaNina Tandon, CEO and co-founder of EpiBone, will deliver the keynote address for the College of Engineering's E-Week on Feb. 22 at 7:30 p.m. in the Willa S. Cather Dining Complex's Red Cloud Suite. EpiBone is the world's first company to grow human bones for skeletal reconstruction.ZawyaEpiBone, Inc. secures funding round led by Kendall Capital PartnersEpiBone, Inc. closed a convertible note funding round led by Kendall Capital Partners, with participation from Lifespan Vision Ventures, EMV Capital plc, and others. The funding will accelerate its pipeline development and global expansion, including exploring Thailand and the UAE as medical tourism centers.FinSMEsEpiBone Raises Funding RoundEpiBone, a regenerative medicine company based in NYC, raised an undisclosed funding amount led by Kendall Capital Partners, with participation from others. The company plans to use the funds for pipeline development of bone and skeletal tissue products.ThemalaysianreserveEpiBone, Inc. Secures Funding Round Led by Kendall Capital Partners to Accelerate Global Expansion of Clinical TrialsEpiBone, Inc. closed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital plc, and others. The funding will support its pipeline development and global expansion of clinical trials, including emerging markets in Thailand and the United Arab Emirates.PR NewswireEpiBone, Inc. Secures Funding Round Led by Kendall Capital Partners to Accelerate Global Expansion of Clinical TrialsEpiBone, Inc. closed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital plc, and others. The funding will support its pipeline development and expansion into Thailand and the United Arab Emirates. The company's technologies include autologous and allogeneic stem cells, 3D bioprinting, and bioreactor technology.VC News DailyEpiBone Scores Funding RoundEpiBone, a regenerative medicine company, has closed a convertible note funding round led by Kendall Capital Partners. The investment includes participation from LifeSpan Vision Ventures and EMV Capital plc, with funds allocated to advance the company's pipeline development for skeletal reconstruction.DVIDSUSAMMDA team marks 2023 successes, sets stage for 2024 and beyondUSAMMDA reported 2023 milestones, including EpiBone's FDA clearance for bone and cartilage testing and a Defense Health Agency award for a snakebite antidote. The team also advanced freeze-dried plasma and portable CT scanners, and combined medical field systems offices. It set the stage for 2024 development.citybizEpiBone CEO Nina Tandon Named to Columbia Engineering Board of VisitorsNina Tandon, CEO and co-founder of EpiBone, has been appointed to the Board of Visitors at Columbia Engineering's Fu Foundation School for a three-year term. The board serves as an advisory group providing guidance on academic standards, strategic planning, and financial support for the school. Tandon brings an insider perspective as a Columbia graduate with degrees in biomedical engineering and healthcare entrepreneurship.